Lipocine (NASDAQ:LPCN) Upgraded by Wall Street Zen to “Hold” Rating

Lipocine (NASDAQ:LPCN) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Sunday.

Other analysts have also issued reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price (up from $7.00) on shares of Lipocine in a research report on Wednesday, January 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Lipocine Price Performance

LPCN stock opened at $8.66 on Friday. The company has a 50 day moving average price of $7.44 and a 200 day moving average price of $4.54. The stock has a market capitalization of $48.06 million, a PE ratio of -8.49 and a beta of 0.99. Lipocine has a fifty-two week low of $2.52 and a fifty-two week high of $12.37.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Citadel Advisors LLC purchased a new position in Lipocine in the third quarter worth about $41,000. Jane Street Group LLC bought a new stake in Lipocine during the fourth quarter valued at about $85,000. Renaissance Technologies LLC raised its position in shares of Lipocine by 3.6% during the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after purchasing an additional 1,300 shares during the period. Finally, Geode Capital Management LLC raised its stake in Lipocine by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock valued at $502,000 after purchasing an additional 1,374 shares during the period. 9.11% of the stock is currently owned by institutional investors.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.